Novo Nordisk agonist shows strong trial results as MASH cases rise among US adults For the first time, a GLP-1 therapy has been cleared to treat metabolic dysfunction-associated steatohepatitis (MASH), after the US Food and Drug Administration (FDA) granted accelerated approval to Novo Nordisks weight-loss drug Wegovy
The mean age was 55.8, 60% of participants were cis-male, there was no trans or non-binary representation and 91% were white
PlexusDx customers also gain access to the Precision Peptide Genetic Test ($298), which analyzes 14 metabolic pathways and 49 peptides to personalize therapy selection based on individual genetic predispositions
The process combines online doctor visits, coaching, prescription access, and medication delivery through a single online platform
Approximately 400 calories, 35g protein Afternoon snack (4:00 PM): Small apple with 1 tablespoon natural peanut butter
TEWL Improvement: A measurable decrease in Trans-Epidermal Water Loss (TEWL), proving a stronger, healthier skin moisture barrier